Danco Laboratories Battles for Mifepristone Mail Access

Danco Laboratories has taken decisive action by filing an application with the U.S. Supreme Court. The pharmaceutical firm's move seeks a stay of an appeals court decision that puts a temporary hold on mail-order access to the abortion drug, mifepristone.

This appeal marks a critical moment in the ongoing legal battles over mifepristone, widely used in medical abortions. The contested ruling threatens the availability of the drug via mail, a method that has become crucial for accessing abortion care.

With this application, Danco Laboratories aims to secure the continued mail-order distribution of mifepristone, arguing the decision to restrict it places undue barriers on reproductive rights.

(With inputs from agencies.)